Exelixis, Ipsen report Phase III data for cabozantinib in HCC

Exelixis Inc. (NASDAQ:EXEL) and partner Ipsen (Euronext:IPN; PINK:IPSEY) reported additional data from the double-blind, international Phase III CELESTIAL trial of cabozantinib to treat advanced hepatocellular carcinoma (HCC). In October, the partners reported that the trial met the primary endpoint of improving median overall survival

Read the full 440 word article

User Sign In